Biothera Pharmaceuticals, Inc. is a leader in novel approaches to cancer immunotherapy based on Pathogen Associated Molecular Patterning molecules, or PAMPs. The Company’s mid clinical-stage compound, Imprime PGG, acts as an immunological “ignition switch” to drive a fully functional, coordinated innate and adaptive immune response to enhance anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic antibodies, and tumor-targeting monoclonal antibodies.
Multiple clinical trials and translational research are planned in 2016 to further optimize potential combinations with Imprime PGG and validate predictive biomarkers for patient selection. Biothera’s programs include strategic partnerships with Merck, Eli Lilly and Company, and Cancer Research UK, clinical collaborations with Dana Farber Cancer Institute and The Mayo Clinic, and research collaborations with Johns Hopkins University, Harvard University, Dartmouth, and the Wistar Institute.
Further, Biothera has assembled a broad intellectual property portfolio for Imprime PGG consisting of more than 100 US & international patents and patents pending. The Company’s leadership team has extensive expertise in development and regulatory strategies, including in oncology. Based on current progress, the Company is seeking to advance Imprime PGG into Phase 2/3 registration trials in multiple cancer indications in 2017-18, with significant milestones anticipated throughout 2016.
Ultimately, Biothera is seeking to offer a new approach to cancer patient care to enhance clinical efficacy and meet ongoing needs in a broad array of cancers. Biothera believes that Imprime PGG represents the next step in immune oncology that can significantly improve the lives of cancer patients.